Exercise missed primary cognitive goals in cancer survivors
In 253 breast cancer survivors, a 12-month exercise program failed to beat wellness calls on primary cognitive tests, despite selective gains in attention and memory.
Journal of the National Cancer Institute
In a randomized controlled trial of 253 breast cancer survivors, researchers tested whether a remotely delivered 12-month exercise program improved cognitive performance compared to a Health & Wellness control arm receiving calls on healthy aging topics. The trial included a six-month intervention followed by a six-month maintenance period. Investigators tracked moderate-to-vigorous physical activity using accelerometers and assessed cognition via self-report questionnaires and objective neurocognitive tests.
The exercise arm increased physical activity from 18 minutes per day at baseline to 23.5 minutes at 12 months, outperforming the control group, which changed from 15 to 15.5 minutes. Despite this increase, the exercise program was not superior to the wellness control for the primary outcomes of self-reported cognition or processing speed. Among secondary outcomes, exercise was associated with greater improvements in attention at six and 12 months, as well as short-term memory benefits at six months.
Why it matters
Cognitive difficulties frequently follow cancer therapies and resemble aspects of accelerated brain aging. Identifying which cognitive domains respond to physical activity helps clinicians define non-pharmacological strategies to support neurological function in survivors.
Caveats
The intervention did not improve primary cognitive endpoints compared to an active wellness control, meaning positive findings were restricted to secondary measures. The trial also exclusively studied breast cancer survivors, limiting generalizability to other populations.
The paper
Show 8 more authors
Loki Natarajan, Tim Ahles, Barton W. Palmer, Dorothy D Sears, Rowena M. Tam, Victoria Mac, Lindsay Dillon, Chang Yan,UC San Diego Health System
Journal of the National Cancer Institute · 30 Sep 2026